TB-500safety profile & UK regulatory status

This page summarises the published safety profile, contraindications, formulation interactions, and UK regulatory status for TB-500 as reported in the pre-clinical research literature. It is a research-orientation reference and not a clinical safety assessment. TB-500 is not licensed as a medicine in the United Kingdom and may not be supplied or administered to humans outside an authorised clinical-trial framework.

Safety profile

Animal studies of both TB-500 (the fragment) and full-length thymosin beta-4 have reported a favourable acute toxicity profile across multiple species and routes of administration. Repeat-dose rodent studies at pharmacologically relevant doses have not revealed organ-level pathology on routine histopathology. Phase I human data from intravenous full-length Tβ4 (RGN-352, RegeneRx) confirmed no dose-limiting toxicities at doses tested; ophthalmic administration (RGN-259) has similarly been well-tolerated in Phase II and Phase III programmes. Common adverse events in the human-trial literature are limited to mild injection-site or topical-application reactions. The principal safety uncertainties for TB-500 specifically are batch composition and long-term immunogenicity. Preparations mislabelled as 'TB-500' may contain full-length Tβ4, the LKKTETQ fragment, or other thymosin-related peptides in varying proportions — this heterogeneity is a specific interpretive problem for both individual research and the aggregate literature, and it is one reason regulatory scrutiny of grey-market TB-500 supply is warranted. The immunogenic potential of repeated exogenous peptide administration — including possible anti-drug antibody formation — has not been systematically evaluated for the fragment. Pro-angiogenic activity, as with BPC-157, raises a theoretical consideration in neoplastic models where enhanced tumour vascularisation could plausibly accelerate growth. No tumour-promotion findings have been reported in the available literature, but the absence of dedicated oncology-safety studies means this concern remains theoretical rather than characterised. Contraindications and precautions on mechanistic grounds include: known malignancy or high-risk premalignant conditions (based on the pro-angiogenic mechanism); pregnancy and lactation (no safety data); active proliferative retinopathy or other pathological neovascularisation contexts. Interactions with concurrent anti-angiogenic medications (bevacizumab, ranibizumab, tyrosine-kinase inhibitors) are pharmacologically plausible but uncharacterised. For laboratory preparations, the standard quality caveats apply: HPLC purity ≥98%, mass-spectrometry identity confirmation, and endotoxin testing (LAL assay, <1 EU/mg) are the minimum requirements for any injectable research preparation. Sterility must be confirmed by standard membrane-filtration or direct-inoculation methods.

UK regulatory status

TB-500 is not licensed as a medicine by the MHRA and has no marketing authorisation in the United Kingdom. The compound has not undergone the clinical development required for product licensing; its use in the UK is strictly restricted to in-vitro and in-vivo pre-clinical laboratory research. Supplying, offering to supply, or advertising for supply of TB-500 to a member of the public engages the Human Medicines Regulations 2012 offences framework, and MHRA has jurisdiction over the promotion and supply of unlicensed medicines regardless of the compound's research-chemical framing. Advertising or promotional material referring to TB-500 for tendon injuries, sports recovery, or any therapeutic claim additionally engages Advertising Standards Authority (ASA) jurisdiction — the ASA has taken action against unlicensed peptide promotional material in analogous contexts. Suppliers positioning TB-500 as a research chemical while offering doses, protocols, or reconstitution guidance oriented to human use are at particular enforcement risk. For competitive athletes, TB-500 is prohibited under the World Anti-Doping Agency Prohibited List category S2 (Peptide Hormones, Growth Factors, Related Substances and Mimetics). This prohibition applies both in-competition and out-of-competition and encompasses all forms and formulations of thymosin beta-4 and its fragments regardless of whether the material is labelled TB-500, thymosin beta-4, or by other commercial designation. Athletes who use TB-500 for any purpose risk anti-doping rule violations under strict liability. Veterinary use in the UK is likewise unlicensed for TB-500 specifically, although related research into thymosin-family proteins has been conducted in equine sports medicine contexts. Racing-industry authorities (British Horseracing Authority) treat TB-500 as a prohibited substance under racing rules regardless of the compound's research-chemical framing. For animal research under the Animals (Scientific Procedures) Act 1986 (ASPA), TB-500 work in vertebrates requires standard project and personal licences. No specific UK enforcement actions relating to TB-500 as a research chemical are recorded in the public domain to date.

What 'research-use-only' means in the UK

The UK regulatory position on research peptides sits across four distinct frameworks: MHRA medicines licensing, the Human Medicines Regulations 2012, the Misuse of Drugs Act 1971, and the WADA Prohibited List. TB-500 is not an MHRA-licensed medicine; possession for bona fide in-vitro or ex-vivo laboratory research is generally lawful, while supply or administration to humans engages the Human Medicines Regulations and is generally an offence. For animal-research use, additional permissions are required under the Animals (Scientific Procedures) Act 1986 (ASPA).

For the comprehensive UK regulatory reference covering all four frameworks, see the UK research peptide regulation 2026 reference.

Practical safety considerations for research

Sterility and endotoxin content of research-grade preparations remain the dominant practical safety variables for any injectable in-vivo work, regardless of the intrinsic safety profile of the active peptide. Batch-to-batch verification of HPLC purity and identity (by mass spectrometry where possible) and endotoxin testing by limulus amebocyte lysate (LAL) assay or recombinant Factor C (rFC) assay are standard due-diligence expectations. For research with vertebrate animals in the UK, ASPA project and personal licences are mandatory and the work must pass a local Animal Welfare and Ethical Review Body assessment.

For full TB-500 research context including mechanism, study citations, and references, see the main TB-500 research profile. For dosing and pharmacokinetic context, see the dosing reference and half-life reference pages.